⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 30, 2024

Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis

Torben Ek Raghda R. Ibrahim Hartmut Vogt Kleopatra Georgantzi Catarina Träger Jennie Gaarder Anna Djos Ida Rahmqvist Elisabeth Mellström Fani Pujol-Calderón Christoffer Vannas Lina Hansson Henrik Fagman Diana Treis Susanne Fransson Tobias Österlund Tzu‐Po Chuang Bronte Manouk Verhoeven Anders Ståhlberg Ruth H. Palmer Bengt Hallberg Tommy Martinsson Per Kogner Martin G. Dalin

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Genomic profiles of tumor DNA generated by SNP microarray

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ek et al. (2024) studied this question.

synapsesocial.com/papers/68e56f7db6db643587510526 https://doi.org/10.1158/2767-9764.27134374

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis2024
2Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis2024
3Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis2024 · 1 citations
4Figure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis2024
5Figure 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis2024